Antimicrobial Resistance (AMR)
AMR is an emerging and devastating global health problem caused directly by over-use of antibiotics. AMR jeopardizes our ability to perform many life-saving procedures such as major surgery and cancer therapy
- In 2019, 1.3 million people died from antibiotic resistant infections, by 2050 as many as 39 million deaths are forecast if the situation is not changed.
AdjuTec Pharma addresses this global problem by developing adjuvant technologies that inhibit key bacterial resistance mechanisms, restoring antibiotic efficacy against life-threatening, multidrug resistant bacterial infections. - Carbapenems (e.g. meropenem) and Cephalosporins (e.g. cefepime) are antibiotics reserved for life-threatening infections. β-lactamases are enzymes produced by bacteria that destroy β-lactamase antibiotics. The bacteria then become resistant to modern antibiotics that may result in potentially deadly infections.
AdjuTec Pharma develops products to inhibit the two main β-lactamase families, serine β-lactamases (SBL) and metallo-β-lactamases (MBL), also called β-lactamase-inhibitors (BLI).
AMR is spreading rapidly across the globe. Globalisation, pandemics, climate change, and war have created the “perfect storm” for resistant bacteria to travel to new territories. While mostly contained in hospitals, resistant bacteria now also spread in the community through wastewater and sewage.
APC301 and APC302 are the best MBL-inhibitor products
Our lead product APC301 (meropenem + APC148 + avibactam) was tested in vitro in 176 MBL- and SBL-producing bacteria (Enterobacterales) against competitor products. APC301 was the most potent product in these highly resistant pathogens. Our follow-up product APC302 (cefepime+APC148+avibactam) showed similar good effects and gives great promise in targeting a broad patient population. To address other serious bacterial infections, we are testing new drug combinations based on our APC148 technology.
Fungi cause diverse diseases in humans, ranging from allergic syndromes to superficial, disfiguring and life-threatening invasive fungal diseases, which together affect more than a billion people worldwide.
Adjutec Pharma is collaborating with academia to find solutions to break fungi resistance.
Adjutec Pharma is collaborating with academia to find solutions to break fungi resistance.
- In 2019, 1.3 million people died from antibiotic resistant infections, by 2050 as many as 39 million deaths are forecast if the situation is not changed.
AdjuTec Pharma addresses this global problem by developing adjuvant technologies that inhibit key bacterial resistance mechanisms, restoring antibiotic efficacy against life-threatening, multidrug resistant bacterial infections. - Carbapenems (e.g. meropenem) and Cephalosporins (e.g. cefepime) are antibiotics reserved for life-threatening infections. β-lactamases are enzymes produced by bacteria that destroy β-lactamase antibiotics. The bacteria then become resistant to modern antibiotics that may result in potentially deadly infections.
AdjuTec Pharma develops products to inhibit the two main β-lactamase families, serine β-lactamases (SBL) and metallo-β-lactamases (MBL), also called β-lactamase-inhibitors (BLI).
AMR is spreading rapidly across the globe. Globalisation, pandemics, climate change, and war have created the “perfect storm” for resistant bacteria to travel to new territories. While mostly contained in hospitals, resistant bacteria now also spread in the community through wastewater and sewage.
APC301 and APC302 are the best MBL-inhibitor products
Our lead product APC301 (meropenem + APC148 + avibactam) was tested in vitro in 176 MBL- and SBL-producing bacteria (Enterobacterales) against competitor products. APC301 was the most potent product in these highly resistant pathogens. Our follow-up product APC302 (cefepime+APC148+avibactam) showed similar good effects and gives great promise in targeting a broad patient population. To address other serious bacterial infections, we are testing new drug combinations based on our APC148 technology.
- Fungi cause diverse diseases in humans, ranging from allergic syndromes to superficial, disfiguring and life-threatening invasive fungal diseases, which together affect more than a billion people worldwide.
Adjutec Pharma is collaborating with academia to find solutions to break fungi resistance.
AdjuTec Pharma's First-in-Class Technology
MBL resistance breaker APC148 destroys vital bacteria resistance mechanisms that prevent the bacteria from destroying antibiotics. APC148 is combined with different antibiotics, e.g. meropenem and cefepime, and other enzyme inhibitors to target different bacteria and patient populations.
All products are covered by approved patents or patent applications.
APC277 is an academic project for treatment of resistant fungal infections.
APC247 is a broad-spectrum BLI product that will be used as an adjuvant also together with last-resort antibiotics. The target indication is patients with complicated Gram-negative infections. The product is in early preclinical development.
FDA has granted AdjuTec Pharma a Qualified Infectious Disease Product designation, giving the company regulatory priority review, access to fast track and rolling review procedures.
A First-in-Human single-dose-ascending study of APC148 alone has been completed. APC148 was shown to be safe and well tolerated and is ready for further clinical development. The regulatory pathway has been discussed with FDA and EMA.
APC301 is AdjuTec Pharma’s lead product that combine meropenem with APC148 and avibactam to secure the efficacy of meropenem. The target indication is patients with complicated infections caused by multidrug-resistant Gram-negative bacteria.
Programs
Programs
APC301 is AdjuTec Pharma’s lead product that combine meropenem with APC148 and avibactam to secure the efficacy of meropenem. The target indication is patients with complicated infections caused by multidrug-resistant Gram-negative bacteria.
A First-in-Human single-dose-ascending study of APC148 alone has been completed. APC148 was shown to be safe and well tolerated and is ready for further clinical development. The regulatory pathway has been discussed with FDA and EMA.
FDA has granted AdjuTec Pharma a Qualified Infectious Disease Product designation, giving the company regulatory priority review, access to fast track and rolling review procedures.
APC247 is a broad-spectrum BLI product that will be used as an adjuvant also together with last-resort antibiotics. The target indication is patients with complicated Gram-negative infections. The product is in early preclinical development.
APC277 is an academic project for treatment of resistant fungal infections.
All products are covered by approved patents or patent applications.
A First-in-Human single-dose-ascending study of APC148 alone has been completed. APC148 was shown to be safe and well tolerated and is ready for further clinical development. The regulatory pathway has been discussed with FDA and EMA.
FDA has granted AdjuTec Pharma a Qualified Infectious Disease Product designation, giving the company regulatory priority review, access to fast track and rolling review procedures.
APC247 is a broad-spectrum BLI product that will be used as an adjuvant also together with last-resort antibiotics. The target indication is patients with complicated Gram-negative infections. The product is in early preclinical development.
APC277 is an academic project for treatment of resistant fungal infections.
All products are covered by approved patents or patent applications.
Pipeline
AdjuTec Pharma portfolio
All products are targeting WHO and CDC critical priority pathogens, with main focus on multidrug-resistant bacterial strains